[HTML][HTML] The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
NYL Ngoi, DSP Tan - Esmo Open, 2021 - Elsevier
The recognition of homologous recombination deficiency (HRD) as a frequent feature of
high-grade serous ovarian cancer (HGSOC) has transformed treatment paradigms. Poly …
high-grade serous ovarian cancer (HGSOC) has transformed treatment paradigms. Poly …
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas
In patients with advanced ovarian carcinomas, the first-line treatment has historically relied
on debulking surgery and platinum-based chemotherapy. If the major therapeutic/prognostic …
on debulking surgery and platinum-based chemotherapy. If the major therapeutic/prognostic …
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: Pathology and molecular biology and early, advanced and recurrent disease
JA Ledermann, X Matias-Guiu, F Amant, N Concin… - Annals of …, 2024 - Elsevier
Highlights•46 participants from 15 countries across Europe, Asia and the USA contributed to
the ESGO–ESMO–ESP consensus conference.•Recommendations cover diagnosis and …
the ESGO–ESMO–ESP consensus conference.•Recommendations cover diagnosis and …
Global characterization of extrachromosomal circular DNAs in advanced high grade serous ovarian cancer
Y Cen, Y Fang, Y Ren, S Hong, W Lu, J Xu - Cell Death & Disease, 2022 - nature.com
High grade serous ovarian cancer (HGSOC) is the most aggressive subtype of ovarian
cancer and HGSOC patients often appear with metastasis, leading to the poor prognosis. Up …
cancer and HGSOC patients often appear with metastasis, leading to the poor prognosis. Up …
Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones
High-grade serous ovarian carcinoma (HGSOC) is genetically unstable and characterised
by the presence of subclones with distinct genotypes. Intratumoural heterogeneity is linked …
by the presence of subclones with distinct genotypes. Intratumoural heterogeneity is linked …
Clinically interpretable radiomics-based prediction of histopathologic response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma
Background Pathological response to neoadjuvant treatment for patients with high-grade
serous ovarian carcinoma (HGSOC) is assessed using the chemotherapy response score …
serous ovarian carcinoma (HGSOC) is assessed using the chemotherapy response score …
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer
RD Morgan, X Wang, BM Barnes, L Spurgeon… - British Journal of …, 2024 - nature.com
Background High-grade serous ovarian cancer (HGSOC) can be treated with platinum-
based neoadjuvant chemotherapy (NACT) and delayed primary surgery (DPS) …
based neoadjuvant chemotherapy (NACT) and delayed primary surgery (DPS) …
Integrating artificial intelligence tools in the clinical research setting: the ovarian cancer use case
L Escudero Sanchez, T Buddenkotte, M Al Sa'd… - Diagnostics, 2023 - mdpi.com
Artificial intelligence (AI) methods applied to healthcare problems have shown enormous
potential to alleviate the burden of health services worldwide and to improve the accuracy …
potential to alleviate the burden of health services worldwide and to improve the accuracy …
[HTML][HTML] British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024
E Moss, A Taylor, A Andreou, C Ang, R Arora… - European Journal of …, 2024 - Elsevier
Recommendations are graded as per the Royal College of Obstetricians and
Gynaecologists document, Clinical Governance Advice No. 1: Guidance for the …
Gynaecologists document, Clinical Governance Advice No. 1: Guidance for the …
GEN-1 in combination with neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer: A phase I dose-escalation study
PH Thaker, WH Bradley, CA Leath III… - Clinical Cancer …, 2021 - AACR
Abstract Purpose: GEN-1 (phIL-12-005/PPC), an IL12 plasmid formulated with
polyethyleneglycol-polyethyleneimine cholesterol lipopolymer, has preclinical activity when …
polyethyleneglycol-polyethyleneimine cholesterol lipopolymer, has preclinical activity when …